Literature DB >> 25185191

Rilotumumab extends PFS in gastric cancer.

.   

Abstract

Patients with gastric or esophagogastric cancer treated with combination chemotherapy and rilotumumab, an anti-HGF monoclonal antibody, had longer progression-free survival than patients treated with chemotherapy alone, according to results from a phase II clinical trial. The survival benefit was greatest in patients with MET-positive disease; a phase III trial testing the drug combination's effect on this patient population is now under way. ©2014 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25185191     DOI： 10.1158/2159-8290.CD-NB2014-113

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  1 in total

1.  Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400.

Authors:  Roy S Herbst; David R Gandara; Fred R Hirsch; Mary W Redman; Michael LeBlanc; Philip C Mack; Lawrence H Schwartz; Everett Vokes; Suresh S Ramalingam; Jeffrey D Bradley; Dana Sparks; Yang Zhou; Crystal Miwa; Vincent A Miller; Roman Yelensky; Yali Li; Jeff D Allen; Ellen V Sigal; David Wholley; Caroline C Sigman; Gideon M Blumenthal; Shakun Malik; Gary J Kelloff; Jeffrey S Abrams; Charles D Blanke; Vassiliki A Papadimitrakopoulou
Journal:  Clin Cancer Res       Date:  2015-02-13       Impact factor: 12.531
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.